H.C. Wainwright analyst Robert Burns raised the price target on Nurix (NASDAQ: NRIX) to $36.00 (from $35.00) while maintaining a Buy rating.

The analyst comments "F4Q24 financial results reported—adjusting price target. Yesterday, Nurix reported its F4Q24 financial results, recording a net loss of $0.75 per share—slightly wider than our previously estimated net loss of $0.64 per share. For F4Q24, Nurix reported $13.3M in collaboration/license revenue vs. our previously estimated $15.0M. R&D and SG&A expenses were $67.2M and $10.7M, respectively, vs. our estimates of $56.6M and $12.1M. Nurix ended F4Q24 with ~$609.6M in cash and cash equivalents; these balance sheet resources should be sufficient to provide an operational runway into 1H27, in our view. After moving our discounted cash flow (DCF)-based valuation assessment forward, we reiterate our Buy rating, while slightly raising our 12-month price target to $36 from the prior $35."